浙江震元(000705.SZ):震元醫藥擬收購震元器化、震元供應鏈兩家全資子公司100%股權
格隆匯5月20日丨浙江震元(000705.SZ)公佈,公司十一屆董事會2024年第二次臨時會議審議通過《關於全資子公司震元醫藥收購震元器化、震元供應鏈兩家全資子公司100%股權的議案》:同意全資子公司紹興震元醫藥經營有限責任公司(以下簡稱“震元醫藥”)按照3,899.72萬元的收購價格,協議收購公司持有的紹興震元醫療器材化學試劑有限公司(以下簡稱“震元器化”)、浙江震元醫藥供應鏈管理有限公司(以下簡稱“震元供應鏈”)兩家全資子公司100%股權,並授權經營班子做好具體事宜。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.